Xcout IntelDenali Therapeutics Inc. competitors & alternatives
The 12 closest competitors and alternatives to Denali Therapeutics Inc. among biotech companies — ranked by similarity to what Denali Therapeutics Inc. actually does, not by market-cap band.
Subscribe to see Denali Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Denali Therapeutics Inc. at a glance
Denali Therapeutics Inc. is a biotech company headquartered in South San Francisco, United States. It is publicly listed (DNLI) with a market capitalisation of $3.1B. Xcout tracks 18 named people at Denali Therapeutics Inc., including Cindy Dunkle (Chief People Officer). Xcout recorded 1 job posting from Denali Therapeutics Inc. in the last 90 days.
Denali Therapeutics Inc. leadership
- Cindy DunkleChief People Officer
- Dana AndersenChief Technical and Manufacturing Officer
- Joe LewcockChief Scientific Officer
- Katie PengChief Commercial Officer
- Peter ChinActing Chief Medical Officer & Head of Development
- Ryan J. WattsCo-Founder, President, Chief Executive Officer & Director
12 more named people on record for Denali Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Denali Therapeutics Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $130M | — | |
| Series A | $217M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Denali Therapeutics Inc.
Xcout recorded 1 job posting from Denali Therapeutics Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Denali Therapeutics Inc.'s hiring signals →
Top 12 Denali Therapeutics Inc. competitors
Ranked by semantic similarity — how close each company is to Denali Therapeutics Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Biotechnology
Arkuda Therapeutics is a biotechnology company developing small-molecule treatments for neurodegenerative diseases, with a focus on restoring lysosomal function and addressing progranulin-related disease biology. Its programs are aimed particularly at patients with frontotemporal dementia and other disorders involving lysosomal dysfunction.
Biotechnology
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Similar biotech company
Prilenia Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead drug candidate, pridopidine, has been studied in Huntington’s disease and amyotrophic lateral sclerosis (ALS), serving patients with serious neurological conditions.
Similar biotech company
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Biotechnology
Delix Therapeutics is a privately held biopharmaceutical company headquartered in Boston, Massachusetts, focused on transforming the treatment of brain health through neuroscience.
Biotechnology
AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.
Similar biotech company
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Biotechnology
Soleno Therapeutics Inc. is a company based in the United States, focused on the development of therapies. It operates as a Neurocrine Biosciences company, with its headquarters located at 100 Marine Parkway, Suite 400.
Biotechnology
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Similar biotech company
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Life Sciences
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Denali Therapeutics Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Denali Therapeutics Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →